Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

被引：888

作者：

Cook, David ^{[1
]}

Brown, Dearg ^{[1
]}

Alexander, Robert ^{[2
]}

March, Ruth ^{[1
]}

Morgan, Paul ^{[1
]}

Satterthwaite, Gemma ^{[1
]}

Pangalos, Menelas N. ^{[1
]}

机构：

[1] AstraZeneca, Innovat Med & Early Dev, Macclesfield SK10 4TG, Cheshire, England

[2] AstraZeneca, Innovat Med & Early Dev, Cambridge, MA 02139 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2014年 / 13卷 / 06期

关键词：

RESEARCH-AND-DEVELOPMENT; NONVALVULAR ATRIAL-FIBRILLATION; THROMBIN INHIBITOR AZD0837; PLACEBO-CONTROLLED TRIAL; VITAMIN-K ANTAGONISTS; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; RECEPTOR ANTAGONIST; PROSTAGLANDIN D-2; DEVELOPMENT PRODUCTIVITY;

D O I：

10.1038/nrd4309

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Maintaining research and development (R& D) productivity at a sustainable level is one of the main challenges currently facing the pharmaceutical industry. In this article, we discuss the results of a comprehensive longitudinal review of AstraZeneca's small-molecule drug projects from 2005 to 2010. The analysis allowed us to establish a framework based on the five most important technical determinants of project success and pipeline quality, which we describe as the five 'R's: the right target, the right patient, the right tissue, the right safety and the right commercial potential. A sixth factor-the right culture-is also crucial in encouraging effective decision-making based on these technical determinants. AstraZeneca is currently applying this framework to guide its R& D teams, and although it is too early to demonstrate whether this has improved the company's R& D productivity, we present our data and analysis here in the hope that it may assist the industry overall in addressing this key challenge.

引用

页码：419 / 431

页数：13

共 71 条

[51]

Quirk M, 2012, INT J NEUROPSYCHOPH, V15, P153

[52] Market withdrawal of new molecular entities approved in the United States from 1980 to 2009 [J].

Qureshi, Zaina P. ;

Seoane-Vazquez, Enrique ;

Rodriguez-Monguio, Rosa ;

Stevenson, Kurt B. ;

Szeinbach, Sheryl L. .

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 (07) :772-777

[53] Quantitative pharmacological analysis of antagonist binding kinetics at CRF1 receptors in vitro and in vivo [J].

Ramsey, Simeon J. ;

Attkins, Neil J. ;

Fish, Rebecca ;

van der Graaf, H. .

BRITISH JOURNAL OF PHARMACOLOGY, 2011, 164 (03) :992-1007

[54] Does size matter in R&D productivity? If not, what does? [J].

Ringel, Michael ;

Tollman, Peter ;

Hersch, Greg ;

Schulze, Ulrik .

NATURE REVIEWS DRUG DISCOVERY, 2013, 12 (12) :901-902

[55] Diagnosing the decline in pharmaceutical R&D efficiency [J].

Scannell, Jack W. ;

Blanckley, Alex ;

Boldon, Helen ;

Warrington, Brian .

NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (03) :191-200

[56] Genomic responses in mouse models poorly mimic human inflammatory diseases [J].

Seok, Junhee ;

Warren, H. Shaw ;

Cuenca, Alex G. ;

Mindrinos, Michael N. ;

Baker, Henry V. ;

Xu, Weihong ;

Richards, Daniel R. ;

McDonald-Smith, Grace P. ;

Gao, Hong ;

Hennessy, Laura ;

Finnerty, Celeste C. ;

Lopez, Cecilia M. ;

Honari, Shari ;

Moore, Ernest E. ;

Minei, Joseph P. ;

Cuschieri, Joseph ;

Bankey, Paul E. ;

Johnson, Jeffrey L. ;

Sperry, Jason ;

Nathens, Avery B. ;

Billiar, Timothy R. ;

West, Michael A. ;

Jeschke, Marc G. ;

Klein, Matthew B. ;

Gamelli, Richard L. ;

Gibran, Nicole S. ;

Brownstein, Bernard H. ;

Miller-Graziano, Carol ;

Calvano, Steve E. ;

Mason, Philip H. ;

Cobb, J. Perren ;

Rahme, Laurence G. ;

Lowry, Stephen F. ;

Maier, Ronald V. ;

Moldawer, Lyle L. ;

Herndon, David N. ;

Davis, Ronald W. ;

Xiao, Wenzhong ;

Tompkins, Ronald G. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (09) :3507-3512

[57] A prostaglandin D2 receptor antagonist modifies experimental asthma in sheep [J].

Shichijo, M. ;

Arimura, A. ;

Hirano, Y. ;

Yasui, K. ;

Suzuki, N. ;

Deguchi, M. ;

Abraham, W. M. .

CLINICAL AND EXPERIMENTAL ALLERGY, 2009, 39 (09) :1404-1414

[58] Glutamate-based antidepressants: 20 years on [J].

Skolnick, Phil ;

Popik, Piotr ;

Trullas, Ramon .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2009, 30 (11) :563-569

[59] Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline:: A potent, selective, and irreversible monoamine oxidase type B inhibitor [J].

Thébault, JJ ;

Guillaume, M ;

Levy, R .

PHARMACOTHERAPY, 2004, 24 (10) :1295-1305

[60] Lebrikizumab in the personalized management of asthma [J].

Thomson, Neil C. ;

Patel, Manish ;

Smith, Andrew D. .

BIOLOGICS-TARGETS & THERAPY, 2012, 6 :329-335

← 1 2 3 4 5 6 7 8 →